Starting July 1, more Australians with rarer cystic fibrosis mutations will gain access to Trikafta through the Pharmaceutical Benefits Scheme, significantly lowering treatment costs. This expansion includes an additional 271 mutations, providing hope for improved quality of life for affected individuals like four-year-old Koah Hart, who has one of the rarest combinations.
